56850-93-2

Basic information

• Product Name: Methyl 4-(2-aminoethoxy)benzoate
• Synonyms: 4-(2-Aminoethoxy)benzoic acid methyl ester;Methyl 4-(2-aminoethoxy)benzoate;Benzoic acid, 4-(2-aMinoethoxy)-, Methyl ester
• CAS NO: 56850-93-2
• Molecular Formula: C₁₀H₁₃NO₃
• Molecular Weight: 195.21512
• EINECS: -0
• Mol File: 56850-93-2.mol
• Article Data: 12

Chemical Properties

• Melting Point: 53-55.5℃
• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Methyl 4-(2-aminoethoxy)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-(2-aminoethoxy)benzoate(56850-93-2)
• EPA Substance Registry System: Methyl 4-(2-aminoethoxy)benzoate(56850-93-2)

Safety Data

• Hazardous Substances Data: 56850-93-2(Hazardous Substances Data)

Usage

Description

Methyl 4-(2-aminoethoxy)benzoate, commonly known as benzocaine, is an organic compound with the molecular formula C10H13NO3. It is a local anesthetic and a medication used to numb the skin or mucous membranes. Benzocaine works by blocking nerve signals in the body, providing temporary pain relief. It is a white, odorless, and tasteless powder that is soluble in water and alcohol, making it easy to incorporate into various topical preparations.

Uses

Used in Pharmaceutical Industry:
Methyl 4-(2-aminoethoxy)benzoate is used as a local anesthetic for minor skin irritations, sunburns, and insect bites. It is incorporated into over-the-counter topical treatments due to its ability to numb the area where it is applied.
Used in Cosmetic Industry:
Methyl 4-(2-aminoethoxy)benzoate is used as a pain-relieving agent in cosmetic products, such as lip balms and other skincare formulations, to provide temporary relief from discomfort and irritation.
Used in Dental Industry:
Methyl 4-(2-aminoethoxy)benzoate is used as a local anesthetic in dental procedures to numb the gums and surrounding tissues, providing patients with a more comfortable experience during dental treatments.

Upstream product

• 151-56-4 ethyleneimine 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 174666-16-1 4-(2-tert-butoxycarbonylaminoethoxy)benzoic acid methyl ester 
• 26690-80-2 2-(N-tert-butoxycarbonylamino)ethanol 
• 56850-91-0 methyl 4-(2-bromoethoxy)benzoate 
• 137988-24-0 methyl 4-(cyanomethoxy)benzoate 
• 113459-58-8 N-[2-(4-Methoxycarbonylphenoxy)ethyl]phthalimide 

Downstream Products

• 174665-27-1 methyl 4-[2-(pyrimidin-2-ylamino)ethyloxy]benzoate 
• 1012058-32-0 (Z)-methyl 4-(2-(5-((5-fluoro-2-oxo-indolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamido)ethoxy)benzoate 
• 174665-28-2 4-[2-(pyrimidin-2-ylamino)ethyloxy]benzoic acid 
• 174665-30-6 3-{4-[2-(pyrimidin-2-ylamino)ethyloxy]benzoylamino}-2(S)-benzenesulfonylaminopropionic acid 
• 174665-29-3 3-{4-[2-(pyrimidin-2-ylamino)ethyloxy]benzoylamino}-2(S)-benzenesulfonylaminopropionic acid tert-butyl ester 
• 783356-68-3 abexinostat 
• 1178873-87-4 methyl 4-[2-({[2-(benzylamino)phenyl]carbonyl}amino)ethoxy]benzoate 
• 1178873-64-7 methyl 4-[2-({4-chloro-2-[(diphenylmethyl)amino]benzoyl}amino)ethoxy]benzoate 
• 866599-49-7 trans 4-[2-(3-benzofuran-2-ylbut-2-enoyl-amino)ethoxy]benzoic acid methyl ester 
• 142783-58-2 4-{2-[3-(6-Chloro-pyridazin-3-yloxy)-2-hydroxy-propylamino]-ethoxy}-benzoic acid methyl ester 

Relevant articles and documents

Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury

Acute kidney injury (AKI) is associated with high morbidity and mortality. Cisplatin is a common chemotherapeutic, but its nephrotoxicity-driven AKI limits its clinical application. Currently, there are no specific and satisfactory therapies in the clinic for AKI. Inhibitors of hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PHD2) or histone deacetylase (HDACs) had shown renoprotective effects against AKI in preclinical studies. This study aimed to develop a novel therapeutic to prevent AKI progression by targeting PHD2 and HDACs simultaneously. We designed and synthesized a series of PHD2/HDACs hybrid inhibitors. The initial drug activity screening identified a candidate compound 31c, which exhibited potent inhibitory activities against PHD2 and HDAC1/2/6. Cellular analyses further showed that 31c did not affect cisplatin's antitumor activity in cancer cells but strongly protected cisplatin-induced toxicity on HK-2 cells. In vivo studies with the cisplatin-induced AKI mouse model demonstrated that 31c remarkably alleviated kidney dysfunction with suppressed plasma BUN/SCr and increased EPO levels. The potent renoprotective effects of 31c on AKI were confirmed by significant improvements in pathological kidney conditions in the mouse model. These results suggest that the novel PHD2/HDACs hybrid inhibitor, 31c, has a clinical potential as the renoprotective agent for the treatment/prevention of cisplatin-induced AKI for various cancers.

Dual inhibitor for prolyl hydroxylase and histone deacetylase, preparation method and application thereof

The invention discloses a new dual inhibitor for prolyl hydroxylase and histone deacetylase shown as formula I, a preparation method and an application thereof. The new dual inhibitor is capable of selectively promoting the level of hypoxia-inducible fact

SUBSTITUTED 2-INDOLINONE AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to substituted 2-indolinone containing zinc- binding moiety based derivatives that have enhanced or unique properties as inhibitors of protein tyrosine kinase (PTK) receptors and their use in the treatment of PTK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.